Examkin

Soru

Zorluk: Çok zorMonitoring and Treatment Evaluation

A 68-year-old man with New York Heart Association (NYHA) class III heart failure with reduced ejection fraction and chronic kidney disease (baseline estimated glomerular filtration rate of 35 mL/min/1.73 m235 \text{ mL/min/1.73 m}^2) is discharged following a 5-day hospitalization for an acute heart failure exacerbation. His volume status has been optimized, and his symptoms are currently stable. His discharge medication regimen includes maximally tolerated doses of metoprolol succinate, newly initiated sacubitril-valsartan, empagliflozin, spironolactone, and a reduced maintenance dose of bumetanide. Which of the following laboratory parameters are strictly indicated for routine serial monitoring during his early outpatient transition phase over the next 1 to 2 weeks? (Select all that apply)

  1. Serum potassium concentrationCevap
  2. Serum creatinine concentrationCevap
  3. C
    Plasma B-type natriuretic peptide (BNP) levels
  4. D
    Urinalysis for glucosuria
  5. E
    Glycosylated hemoglobin (HbA1c) fraction

Cevap

The parameters that must be strictly monitored are the serum potassium concentration and the serum creatinine concentration.
Guideline-directed medical therapy for heart failure with reduced ejection fraction utilizes combinations of medications (such as ARNIs, MRAs, and SGLT2 inhibitors) that profoundly influence renal hemodynamics and electrolyte clearance. In a patient with baseline chronic kidney disease, the concurrent blockade of the renin-angiotensin-aldosterone system with sacubitril-valsartan and spironolactone poses a severe risk for life-threatening hyperkalemia. Simultaneously, the tubuloglomerular feedback mechanisms activated by empagliflozin, combined with the efferent vasodilation from the ARB component and volume reduction from loop diuretics, predictably decrease the glomerular filtration rate. Current treatment guidelines universally recommend measuring serum electrolytes (specifically potassium) and renal function (creatinine/blood urea nitrogen) within 1 to 2 weeks of discharge or medication titration to distinguish benign, expected initial fluctuations from dangerous acute kidney injury or hyperkalemia.

Adım Adım Çözüm

1
Analyze the patient's new pharmacotherapeutic regimen and baseline comorbidities.
The patient has Stage 3b chronic kidney disease and is taking a multidrug regimen including sacubitril-valsartan, spironolactone, empagliflozin, and bumetanide.
Identifying overlapping toxicities and mechanisms of action is essential to anticipate adverse events during care transitions.
2
Evaluate the risk profile of the regimen on renal hemodynamics and electrolytes.
The combination of an ARNI (sacubitril-valsartan) and a mineralocorticoid receptor antagonist (spironolactone) severely impairs potassium excretion, while the addition of an SGLT2 inhibitor (empagliflozin) and a loop diuretic (bumetanide) reduces intravascular volume and alters intraglomerular pressure.
Patients with preexisting chronic kidney disease are highly susceptible to sudden hemodynamic shifts, predisposing them to hyperkalemia and acute kidney injury.
3
Assess the clinical utility of the other proposed laboratory tests in this specific timeframe and pharmacological context.
BNP is artificially elevated by sacubitril and cannot be used; glucosuria is a mandatory physiologic consequence of empagliflozin; and HbA1c requires months to reflect clinical changes.
Test selection must be timely, accurate in the presence of interfering drugs, and capable of generating actionable clinical decisions.

Anahtar Kavram

Early outpatient monitoring for patients initiated on comprehensive guideline-directed medical therapy for heart failure (particularly ARNIs, MRAs, and SGLT2 inhibitors) must prioritize serum potassium and creatinine due to the high risk of hyperkalemia and hemodynamic acute kidney injury, while recognizing that ARNIs invalidate standard BNP measurements.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru